Spain: Antiseptics for skin use in the context of a surgical treatment or an injection will be treated as medicinal products

In brief

On 12 August 2021, the Spanish Agency of Medicinal Products and Medical Devices (AEMPS) published a briefing note on the new regulatory framework applicable to antiseptics intended for the disinfection of the surgical site prior to surgery or to the injection point ("Briefing note"). Said products had been regarded by the Spanish regulator as biocidal products until the publication of a Resolution dated 2 June 2021 which reclassified them as medicinal products. Companies concerned by such regulatory amendment should note, however, that there is a transitional period so they will be able to adapt to the new requirements stemming from the classification as medicinal products: this transitional period will extend until 1 June 2022.


Contents

A closer look 

Following the footsteps of other European authorities, last 2 June 2021 the Spanish Agency of Medicinal Products and Medical Devices amended the legal classification of antiseptics for use on human skin with the intended purpose of cleaning and disinfecting a surgical site or injection area.

Considering their use in a pre-surgery or injection context, these antiseptics can get into the body thus making likely the unfolding of unintended effects. To account for this, the AEMPS ceased to consider these products as biocides for healthy skin (as established in a previous note published back in 2011) and reclassified them as medicines.

This reclassification excludes, though, antiseptics for healthy skin merely intended for the surgical cleaning of hands.

Resulting from the amendment above, companies marketing these antiseptics face two major consequences which the AEMPS explains in-depth in its Briefing note: 

  • Product marketing authorizations. Companies shall have their antiseptics evaluated and authorized pursuant to the regulations on medicinal products (specifically Royal Decree 1345/207 of 11 October) before placing them on the market. In this sense, labelling shall also comply with rules applicable to medicinal products.
  • Manufacturing requirements. Companies shall also obtain an operating permit as a manufacturer of medicinal products to be able to lawfully manufacture these antiseptics. To do so, they are required to follow the application process set out in Royal Decree 824/2010, which includes an inspection prior to the issuance of the authorization.

To streamline the transition and compliance with new requirements, the AEMPS granted companies a transitional period during which they will be able to market the relevant antiseptics which have been already authorized as biocidal products, ending on 1 June 2022. 

In order to help companies navigate the new regulatory regime, the AEMPS has also published a Q&A section on its website. This includes valuable insights into the new regime. Namely, it clarifies that antiseptics covered by the regulatory change are not any antiseptic for skin disinfection or hospital use but only those intended for cleaning and disinfection of a site prior to surgery or an injection area. On another note, it clarifies that those products currently marketed as biocidal products that remain on the market beyond 1 June 2022 can be sold until end of stock. 


Copyright © 2022 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.